CLINICAL R&D PROGRAM UPDATES

Our ground-breaking research in the field of nanotechnology, specifically extracellular vesicles and perinatal-derived nanoparticles, has created a novel biologic candidate that represents the next frontier of regenerative medicine. ZEO ScientifiX™ is committed to creating life changing and lifesaving therapies for important clinical conditions.

OSTEOARTHRITIS (OA)

ZEO ScientifiX™ received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application on our lead product, Zofin™, for the treatment of knee osteoarthritis. We completed a Phase 1 study for knee osteoarthritis and established the safery of our exosome therapeutics. A double blinded, placebo-controlled, phase II trial investigating the safety and efficacy of Zofin™ for patients suffering with knee osteoarthritis is planned for 2024

Chronic Obstructive Pulmonary Disease (COPD)

ZEO ScientifiX™ received approval from the (FDA) for an Investigational New Drug (IND) application on our lead product, Zofin™, in the treatment of patients diagnosed with COPD. This approved trial design will be a double blinded, placebo-controlled, phase I/II trial investigating the safety and potential efficacy of intravenous infusion (IV) of Zofin™ for the treatment of COPD.

COVID-19

ZEO ScientifiX™ has completed a Phase I in patients with moderate to severe COVID-19 as well as a separate Phase 1 study in patient with “long-haul” COVID-19. The FDA also granted the company an expanded access IND that provided additional patients with COVID-19 access to Zofin outside of the formal clinical trial. This expanded access protocol provides access to Zofin for patients in outpatient and inpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19 infection, or who are judged by a healthcare provider to be at high risk of progression to moderate disease.
The trial is being conducted at the United Memorial Medical Center in Houston, TX. ZEO ScientifiX™ is committed to completing our FDA-approved clinical trials as we hope to develop an FDA-approved treatment for multiple clinical conditions.